Skip to main content
. 2022 Nov 11;13:950144. doi: 10.3389/fimmu.2022.950144

Table 1.

Clinical characteristics of RA patients and controls.

Variables Healthy control (n = 73) Rheumatoid arthritis (n = 62)
All (n = 62) DAS28-ESR ≤ 3.2 (n = 13) 3.2 < DAS28-ESR ≤ 5.1 (n = 25) DAS28-ESR > 5.1 (n = 24)
Female, n (%) 48 (65.8) 43 (69.4) 8 (61.5) 20 (80.0) 15 (62.5)
Age (years) 49.6 ± 10.6 53.3 ± 10.0 46.3 ± 10.2 54.2 ± 7.7 56.3 ± 10.4
Duration (m) 3.0 (2.0–12.0) 4.0 (3.0–10.0) 3.0 (2.0–12.0) 3.0 (2.0–10.5)
RF (KU/L) 72.2 (18.5–175.1) 52.2 (9.0–212.9) 72.4 (25.4–158.4) 72.7 (14.1–214.9)
Anti-CCP (U/ml)* 89.6 (12.2–200.0) 200.0 (0.5–200.0) 70.4 (18.2–200.0) 84.5 (5.4–200.0)
ESR (mm/h) 37.5 (21.5–54.0) 17.0 (4.5–28.0) 36.0 (19.5–46.5) 53.5 (33.5–68.8)
DAS28-ESR 4.50 (3.33–5.58) 2.59 (2.29–2.90) 4.25 (3.76–4.67) 5.94 (5.51–6.38)
Stiffness, n (%) 27 (43.5) 1 (7.7) 11 (44.0) 15 (62.5)

*Six RA patients lack anti-CCP antibody data. TJC28, Tender Joint Count 28 Joints; SJC, Swollen Joint Count 28 Joints; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate. DAS28-ESR, Disease Activity Score in 28 Joints System with Erythrocyte Sedimentation Rate, formula: DAS28-ESR = [0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.70 * Ln(ESR)] * 1.08 + 0.16.